Format

Send to

Choose Destination
Int J Biochem Cell Biol. 2016 Sep;78:173-179. doi: 10.1016/j.biocel.2016.07.011. Epub 2016 Jul 15.

Management of non-small cell lung cancer in the era of personalized medicine.

Author information

1
Thoracic Surgery, Istituto Nazionale per lo Studio e la Cura dei Tumori 'Fondazione Giovanni Pascale' - IRCCS, Napoli, Italy.
2
Medical Oncology, Istituto Nazionale per lo Studio e la Cura dei Tumori 'Fondazione Giovanni Pascale' - IRCCS, Napoli, Italy.
3
Experimental Pharmacology, Istituto Nazionale per lo Studio e la Cura dei Tumori 'Fondazione Giovanni Pascale' - IRCCS, Napoli, Italy.
4
Radiation Oncology, Istituto Nazionale per lo Studio e la Cura dei Tumori 'Fondazione Giovanni Pascale' - IRCCS, Napoli, Italy.
5
Interventional Radiology, Istituto Nazionale per lo Studio e la Cura dei Tumori 'Fondazione Giovanni Pascale' - IRCCS, Napoli, Italy.
6
Experimental Pharmacology, Istituto Nazionale per lo Studio e la Cura dei Tumori 'Fondazione Giovanni Pascale' - IRCCS, Napoli, Italy. Electronic address: a.budillon@istitutotumori.na.i.

Abstract

Despite major advances in the molecular definition of the disease, screening and therapy, non-small cell lung cancer (NSCLC) is still characterized by a disappointing overall survival, depending on subtype and tumor stage. To address this challenge, in the last years the therapeutic algorithm of NSCLC has become much more complex and articulated, with different kinds of drugs, including chemotherapy, targeted-based agents, angiogenesis inhibitors and immunotherapy, and multiple lines of treatments, for patients with squamous and non-squamous hystology, EGFR mutation and ALK rearrangement. This short viewpoint describes the emerging strategies for the management of NSCLC, indicating how a personalized approach, characterized by a specific multidisciplinary involvement, implies a process that starts with early detection and includes surgery and systemic therapy.

KEYWORDS:

ALK; EGFR; Early detection; Immunotherapy; Non-small cell lung cancer (NSCLC); Personalized medicine; Stereotactic ablative radiotherapy (SABR); Video-assisted thoracoscopic surgery (VATS)

PMID:
27425397
DOI:
10.1016/j.biocel.2016.07.011
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center